scripod.com

OpenAI Calls a ‘Code Red’ + Which Model Should I Use? + The Hard Fork Review of Slop

Hard Fork

2025/12/05
Hard Fork

Hard Fork

2025/12/05

Shownote

It’s A.I. model rollout season in Silicon Valley, and OpenAI appears to be feeling the pressure. Sam Altman, the chief executive of OpenAI, sent a memo to staff on Monday declaring a “code red” effort to improve ChatGPT and delay other initiatives. We expl...

Highlights

The AI landscape is shifting rapidly as major tech players intensify their race for dominance. With new model releases and strategic pivots unfolding in real time, the pressure is mounting on industry leaders to innovate faster and smarter. OpenAI, once ahead of the curve, now finds itself reacting to bold moves from competitors.
05:56
Google can subsidize AI models to drive down costs and capture market share
16:31
ChatGPT 5.1 and Gemini 3 show flaws when generating content based on an unpublished study
21:39
Claude Opus 4.5 has an empathy for users that feels genuine and distinct
26:51
A 'Soul Document' explaining Claude's purpose was found in its model weights
29:40
Anthropic's enterprise success is costing OpenAI significant revenue
34:50
AI is like a higher-resolution JPEG, getting clearer over time
37:43
Those who don't use AI have no valid opinion on its capabilities.
53:46
A Whirlpool ad using an unauthorized AI-generated voice of a state senator won and then lost Cannes Lions awards.
1:01:45
By 2025, slop will be a medium with good and bad content.

Chapters

Is OpenAI Losing Its Edge in the AI Race?
00:00
Why Is Google Catching Up So Fast?
05:56
How Does Gemini 3 Stack Up Against the Competition?
14:09
Which AI Feels More Human: ChatGPT, Gemini, or Claude?
18:56
What’s Behind Anthropic’s Rise in the Enterprise World?
24:08
Is Anthropic Becoming OpenAI’s Biggest Threat?
29:40
How Do You Pick the Right AI for Your Needs?
34:50
Are AI Advances Actually Changing the Economy?
37:43
When Does AI Help — and When Does It Harm?
43:13
Could 'Slop' Become the Next Big Medium?
59:07

Transcript

Kevin Roose: This podcast is supported by Pharma. Picture this. A big hospital system pays $400 for a cancer medicine, but the charge on the patient's bill? More than $5,000. That's what happens when hospitals abuse the 340B program. They can mark up medic...